Core Insights - The announcement from the company indicates positive topline pharmacokinetic (PK) data for ASC30, an oral tablet administered once daily, in a Phase Ib multiple ascending dose (MAD) study involving obese subjects with a BMI of 30-40 kg/m² [1][2] - The study demonstrated that higher drug exposure levels correlate with more significant weight loss, with a 4.5% reduction in weight for the 20 mg cohort and a 6.5% reduction for the 40 mg cohort after 28 days of treatment [1][3] Group 1: Pharmacokinetics and Weight Loss - In the Phase Ib MAD study, the drug exposure levels (AUC0-24h) for the 20 mg and 40 mg cohorts were 3,560 ng.h/mL and 5,060 ng.h/mL, respectively [1] - The weight loss results were consistent with the drug exposure levels, indicating that higher exposure leads to more pronounced weight loss effects [1][3] Group 2: Comparison with Orforglipron - ASC30's drug exposure levels were approximately 2.3 times and 3.3 times higher than those of orforglipron (24 mg cohort), which had an AUC0-24h of 1,520 ng.h/mL [2] - The weight loss achieved with orforglipron after 28 days was only 3.6%, indicating that ASC30 may offer superior efficacy in weight reduction [2] Group 3: Safety and Tolerability - The ASC30 oral tablet demonstrated good safety and tolerability, with no serious adverse events (SAEs) reported and no grade 3 or higher adverse events observed [3] - No elevations in liver enzymes or other abnormalities were noted during the study, suggesting a favorable safety profile for ASC30 [3] Group 4: Competitive Positioning - The company believes that the higher drug exposure levels of ASC30 will lead to more significant weight loss compared to other small molecule GLP-1 receptor agonists, including orforglipron [3] - The data from non-human primate studies, which showed higher drug exposure for ASC30, has been successfully translated into human clinical research, enhancing the competitive and differentiated potential of ASC30 in treating obesity [3]

Group 1 - Company Gilead Sciences-B (01672.HK) announced positive topline pharmacokinetic (PK) data from a randomized, double-blind, placebo-controlled Phase Ib multiple ascending dose (MAD) study of ASC30 in obese subjects (BMI: 30-40 kg/m2) [1] - In the Phase Ib MAD study, the drug exposure levels (AUC0-24h) at steady state were 3,560 ng.h/mL for cohort 1 (20 mg) and 5,060 ng.h/mL for cohort 2 (40 mg) [1] - After 28 days of treatment, the average weight loss was 4.5% for cohort 1 and 6.5% for cohort 2, indicating that higher drug exposure leads to more significant weight loss effects [1] Group 2 - The founder and CEO of Gilead, Dr. Wu Jinzi, stated that higher drug exposure levels for small molecule GLP-1 receptor agonists, including orforglipron, result in more significant weight loss effects [2] - In head-to-head studies in non-human primates, ASC30 showed higher drug exposure than orforglipron, which translated into human clinical studies [2] - Cross-trial comparisons indicated that ASC30's drug exposure in humans is approximately 2.3 to 3.3 times that of orforglipron, suggesting competitive and differentiated potential for ASC30 in treating obesity [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 「基於目前已公開的臨床數據，我們相信對於包括orforglipron在內的小分子GLP-1 受體(GLP-1R)激動劑而言，更高的藥物暴露量會產生更顯著的減重效果，」歌禮 創始人、董事會主席兼首席執行官吳勁梓博士表示，「在非人靈長類動物頭對頭研 究中，ASC30藥物暴露量高於orforglipron，這個數據進一步轉化到了人體臨床研 究中。跨試驗對比顯示，ASC30在人體中的藥物暴露量約為orforglipron的2.3倍至 3.3倍，我們對此感到非常激動。鑒於ASC30更高的藥物暴露量在肥胖受試者中產 生了更顯著的減重效果，我們相信，與orforglipron相比，ASC30每日一次口服片 治療肥胖症具有競爭性及差異化潛力。」 茲提述本公司日期為2025年8月5日的公告，本公司於該公告 ...

Market Overview - The Hong Kong stock market experienced a significant decline in the afternoon, with the Hang Seng Index dropping by 1.27%, losing over 300 points. The Hang Seng China Enterprises Index and the Hang Seng Tech Index fell by 1.4% and 1.47% respectively, with the former barely holding above the 9000-point mark [2] - Major technology stocks, which serve as market indicators, continued to decline in the afternoon. Kuaishou and Meituan fell over 3%, while JD.com dropped by 2.5%. Baidu, NetEase, and Tencent saw declines close to 2%, and Xiaomi fell by 0.56%. Alibaba managed to stay slightly positive [3] Sector Performance - The financial sector, including banks, insurance companies, and Chinese brokerage firms, collectively underperformed, contributing to the overall market decline. The performance of individual stocks continued to be affected by ongoing earnings reports, with property management and real estate stocks experiencing significant drops [3] - Biopharmaceutical stocks faced a collective downturn, particularly in the innovative drug sector, following comments from Trump regarding the rapid imposition of tariffs on pharmaceuticals. This led to notable declines in various biopharma stocks [3] Specific Stock Movements - Several biopharmaceutical companies saw substantial declines, including Kanghao Ya-B (-8.59%), Qiansirui Biotechnology (-7.42%), and Kangfang Biotechnology (-7.10%). Other notable decliners included Xiansheng Pharmaceutical (-6.79%) and Shiyao Group (-6.36%) [3] - In contrast, the rare earth sector remained strong, benefiting from the implementation of supply reforms and multiple catalysts. Apple’s upcoming event on September 9, where the iPhone 17 series is expected to be launched, led to a rise in Apple-related stocks, with Lens Technology (300433) surging nearly 8% and reaching a new high since its listing [4]

Group 1: Market Overview - The Hang Seng Index fell by 0.22%, down 56 points, closing at 25,773 points, while the Hang Seng Tech Index rose by 0.27% [1] - The early trading volume in the Hong Kong stock market reached 133.9 billion HKD [1] Group 2: Company Performances - Pop Mart (09992) surged by 2.88%, with new products selling out instantly and continued high growth in H1 performance [1] - China Duty Free Group (01880) soared over 5% following the opening of its first city duty-free store in Guangzhou, with multiple city stores entering the cultivation phase [1] - Genscript Biotech (01672) increased by 4.7%, as the company raised funds to enhance its weight loss drug development, with Citigroup suggesting attention on the upcoming ASC30 Phase II data [1] - China Gold International (02099) rose by 6.8%, reaching a new high, with core product output exceeding half of the annual guidance and significant expansion potential at the Jiamar mine [1] - Meitu (01357) saw an early gain of over 7%, officially entering the MSCI China Index, with Morgan Stanley optimistic about the company's long-term growth potential [1] - Innovent Biologics (02696) increased by 5.68% post-earnings, with ongoing internationalization strategy and overseas product profits more than doubling in H1 [1] - Angelalign Technology (06699) rose over 7%, with H1 net profit increasing by over 360%, and declared a special interim dividend of 0.46 HKD [1] - Oriental Selection (01797) fell over 7%, with annual net profit declining by 99.67%, while Goldman Sachs maintained a "sell" rating [1][2] Group 3: Financial Results - Kintor Pharmaceutical (01951) dropped by 5.97% post-earnings, reporting a loss of 1.04 billion CNY in H1, compared to a profit in the same period last year [2]

Group 1 - The core point of the article is that Gilead Sciences-B (01672) announced a share placement to raise funds for clinical trials related to obesity treatments, which has positively impacted its stock price [1] - Gilead plans to place 52.4 million shares at HKD 16.45 each, representing a discount of approximately 9.9% from the previous closing price, with net proceeds expected to be HKD 468 million [1] - Approximately 90% of the funds raised will be allocated to the development of subcutaneous and oral peptide candidates for obesity clinical trials [1] Group 2 - The controlling shareholder and founder, Wu Jinzi, will sell 52.4 million shares at HKD 16.45 each and subsequently subscribe to 28.82 million new shares, resulting in a cash-out of HKD 388 million [1] - Citigroup has highlighted the potential of Gilead's small molecule GLP-1 receptor agonist ASC30, with phase II data expected to be released in Q4 this year, which could serve as a key catalyst for the company [1] - Management has indicated that the safety data from the ASC30 phase II A group blind clinical trial has shown good performance with no cases of discontinuation, and a business development partnership for ASC30 is anticipated by mid-2026 [1]

花旗发布研报称，关注歌礼制药具备同类最佳潜力的小分子GLP-1受体激动剂ASC30，将于今年第四季 发表二期数据，相信可成为公司关键催化剂。管理层透露截至目前ASC30二期A组盲法临床试验安全性 数据表现良好，无任何中止案例，预期最迟于2026年上半年就ASC30达成业务发展合作。此外，花旗认 为歌礼包括ASC47及ASC50等其他候选药物仍未获市场充分认可，若未来有新数据公布，预料可带来潜 在上行空间。 歌礼制药-B(01672)早盘涨超5%，截至发稿，涨3.9%，报14.38港元，成交额5323.98万港元。 消息面上，歌礼制药近日公告称，拟以先旧后新方式配售5240万股股份，每股16.45港元，较前一日收 盘价折让约9.9%，所得款项净额4.68亿港元，约90%建议用于其皮下注射多肽及口服多肽候选药物有关 的肥胖症临床试验研发。同时，歌礼制药的控股股东、创办人吴劲梓还将以每股16.45港元的价格先出 售5240万股股份，再认购2882万股新股，即控股股东配股套现3.88亿港元。 ...

Group 1 - Rongchang Biologics (09995.HK) increased by 7.44% [1] - Yongtai Biologics-B (06978.HK) rose by 5.69% [1] - Gilead Sciences-B (01672.HK) saw a gain of 4.41% [1] - Laika Pharmaceuticals-B (02105.HK) experienced a rise of 3.18% [1]

歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认购协议,根据一般 授权配发及发行2882万股新股份。 ...

智通财经APP讯，歌礼制药-B(01672)发布公告，于2025年8月25日根据日期为2025年8月19日的配售及认 购协议, 根据一般授权配发及发行2882万股新股份。 ...